HR Execs on the Move

Orbus Therapeutics

www.orbustherapeutics.com

 
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Elite Research Network

Elite Research Network, LLC is a Mount Pleasant, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Eagle Hospital Physicians

Eagle Hospital Physicians is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heartland Health Care Ctr

Heartland Health Care Ctr is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health-E-Quip

Health-E-Quip is a Hutchinson, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.